Stereotaxis(STXS) - 2025 Q4 - Annual Results

Exhibit 99.1 "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high density mapping catheter. This core product port ...